Palivizumab

What is Palivizumab?

Palivizumab is a specialized medication, specifically a monoclonal antibody, designed to protect certain vulnerable populations from severe disease caused by the Respiratory Syncytial Virus (RSV). Marketed under the brand name Synagis, it plays a vital role in preventing serious lower respiratory tract infections that can lead to hospitalization, particularly in high-risk infants and young children. Unlike a vaccine, which stimulates the body's own immune system, palivizumab provides immediate, temporary protection through passive immunity by directly supplying antibodies.

RSV is a common respiratory virus that usually causes mild, cold-like symptoms. However, in certain at-risk groups, it can lead to severe complications such such as bronchiolitis (inflammation of the small airways in the lungs) and pneumonia. Palivizumab is not used to treat an existing RSV infection but rather to prevent it or reduce its severity during the typical RSV season.

How Does it Work?

The mechanism of action for Palivizumab is quite specific and effective. RSV, like many viruses, needs to attach to and enter host cells to replicate and cause infection. The virus uses a specific protein on its surface, known as the F (fusion) protein, to facilitate this entry.

Palivizumab is an antibody that is engineered to recognize and bind to a specific site on the F protein of the RSV. By binding to this site, palivizumab essentially blocks the virus's ability to fuse with and enter the cells lining the respiratory tract. This neutralization prevents the virus from infecting cells and replicating, thereby significantly reducing the viral load and the likelihood of developing severe RSV-related illness. Because it directly provides pre-formed antibodies, its protective effect is immediate but temporary, lasting for approximately one month after each dose.

Medical Uses

Palivizumab is a critical preventative medication indicated for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of severe RSV disease. It is not recommended for routine use in all infants, but rather for those who are most vulnerable to the severe outcomes of RSV infection. The primary groups for whom palivizumab is typically prescribed include:

• Premature Infants: Infants born at 35 weeks gestational age or less and who are 6 months of age or younger at the beginning of the RSV season.
• Children with Chronic Lung Disease (CLD) of Prematurity: Children born prematurely who required medical therapy (e.g., supplemental oxygen, bronchodilator, diuretic, or corticosteroid therapy) for CLD within 6 months of the start of the RSV season.
• Children with Hemodynamically Significant Congenital Heart Disease (CHD): Children less than 12 months of age with certain types of CHD that are considered hemodynamically significant (meaning they affect blood flow in a way that can worsen RSV outcomes).
• Children with Neuromuscular Conditions: Children who have neuromuscular disease or lung abnormalities that impair the ability to clear airway secretions.
• Children with Immunodeficiency: Children who are severely immunocompromised may also be candidates.

It's crucial to understand that Palivizumab is a prophylactic measure, meaning it's given before exposure to the virus to prevent illness, not to treat an active infection.

Dosage

The recommended dose of Palivizumab is 15 mg/kg of body weight, administered once a month via intramuscular injection. The injections are typically given during the local RSV season, which usually spans 5 to 7 months. Healthcare providers determine the exact start and end dates of the RSV season in their specific region. For most eligible patients, a total of five monthly doses are administered throughout the season.

It is important that each dose is given approximately 30 days apart to ensure continuous protection during the entire RSV season. Missing a dose or delaying an injection can leave the child vulnerable to RSV infection. The injection is usually given in the anterolateral aspect of the thigh, as this muscle is well-developed in infants and young children. The deltoid muscle may be used for older children if adequate muscle mass is present.

Side Effects

Like all medications, Palivizumab can cause side effects, although not everyone experiences them. Most side effects are mild and temporary. Common side effects reported include:

• Fever
• Rash
• Pain, redness, or swelling at the injection site
• Upper respiratory tract infection symptoms (e.g., runny nose, cough)
• Diarrhea
• Vomiting

More serious, though rare, side effects can occur, including severe allergic reactions (anaphylaxis). Signs of a severe allergic reaction may include difficulty breathing, wheezing, hives, severe rash, dizziness, or swelling of the face, lips, or tongue. If any signs of a severe allergic reaction occur, immediate medical attention is necessary. Parents and caregivers should discuss all potential risks and benefits with their healthcare provider before their child receives palivizumab.

Drug Interactions

Generally, Palivizumab has a low potential for drug interactions. Since it is a monoclonal antibody and not metabolized by the cytochrome P450 enzyme system, it is unlikely to interact with medications that are processed through these pathways. However, it is always important to inform your healthcare provider about all medications your child is currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.

There is no known interaction between palivizumab and routine childhood vaccines. In fact, infants and children receiving palivizumab should continue to receive their recommended vaccinations according to the standard immunization schedule. However, it's generally advised to administer palivizumab and other injectable vaccines at different sites to avoid confusion regarding injection site reactions. As a precaution, some healthcare providers may recommend a slight delay between Palivizumab administration and live virus vaccines, though this is often not a clinical concern given the passive nature of the immunity provided by palivizumab.

FAQ

What is RSV?

RSV, or Respiratory Syncytial Virus, is a common respiratory virus that typically causes mild, cold-like symptoms. However, it can lead to serious lung infections like bronchiolitis and pneumonia, especially in infants and young children with underlying health conditions.

Who is considered a high-risk infant for RSV?

High-risk infants include those born prematurely (35 weeks gestation or less), children with chronic lung disease of prematurity, and those with certain types of congenital heart disease. Other immunocompromised children may also be considered high-risk.

Is Palivizumab a vaccine?

No, Palivizumab is not a vaccine. It's a monoclonal antibody that provides immediate passive immunity by directly supplying antibodies. A vaccine stimulates the body to produce its own antibodies over time.

How long does the protection from Palivizumab last?

Each dose of palivizumab provides protection for approximately one month. Therefore, it is administered monthly throughout the RSV season to maintain continuous protection.

Can my child still get RSV if they receive Palivizumab?

While palivizumab significantly reduces the risk of severe RSV disease and hospitalization, it does not offer 100% protection from all RSV infections. Children receiving palivizumab can still contract RSV, but the infection is likely to be less severe.

Products containing Palivizumab are available through trusted online pharmacies. You can browse Palivizumab-based medications at ShipperVIP or Medicenter.

Summary

Palivizumab is a vital preventative medication for specific groups of high-risk infants and young children, offering crucial protection against severe Respiratory Syncytial Virus (RSV) disease. As a monoclonal antibody, it provides immediate passive immunity by blocking the virus's ability to infect cells. Administered monthly during RSV season, it significantly reduces the likelihood of serious complications, offering a critical layer of defense for the most vulnerable populations. While generally well-tolerated, it is essential for parents and caregivers to understand its purpose, dosage, and potential side effects, working closely with healthcare providers to ensure optimal protection for their child.